Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
Part of Cancer clinical trials.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, age 18 to 75
- You have confirmed HER2-positive invasive breast cancer (a biopsy showed this)
- Your cancer is stage II or III, and you have not started any cancer treatment yet
- Your overall health/activity level is ECOG 0–1 (you can do most daily activities)
- Your kidneys, liver, and other organs work well enough for study drugs
- You must not have received any prior anti-cancer treatment (chemo, radiation, targeted pills, or hormone/endocrine therapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This trial tests a targeted drug called pyrotinib for women with HER2-positive early or locally advanced breast cancer. It aims to see if adding this treatment before surgery improves outcomes.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This trial combines two targeted medications (SHR-A1811 and pyrotinib) for people with HER2-positive breast cancer that has spread or cannot be removed with surgery. It is for those whose cancer has stopped responding to previous HER2-targeted therapies or chemotherapy.
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
This trial tests a drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after 4 cycles of standard pre-surgery treatment. The goal is to see if this drug can help improve outcomes before surgery.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.